

---

**ENTRY INTO LOAN AGREEMENT BY CHINA MERCHANT LIPPO CHANGSHU O&G HOSPITAL CO., LTD**

---

1. The Board of Directors (the "**Board**") of OUE Lippo Healthcare Limited (the "**Company**") wishes to announce that China Merchant Lippo Changshu O&G Hospital Co., Ltd. (常熟招商力宝妇产医院有限公司) (the "**Hospital Company**"), an associated company of the Company, has entered into a loan agreement (the "**Loan Agreement**") with China Construction Bank, Changshu (the "**Lender**") for the grant of a loan of RMB 115 million (approximately SGD 24 million<sup>1</sup>) (the "**Loan**") to the Hospital Company. The tenure of the Loan is 15 years, subject to the terms and conditions of the Loan Agreement. The Loan Agreement will be effective from the date of this announcement.
2. The Hospital Company is the operating company of the China Merchant-Lippo obstetrics and gynaecology hospital in Changshu (the "**Changshu Hospital**"). The Hospital Company is wholly owned by China Merchants Lippo Hospital Management (Shenzhen) Limited ("**CMLHM**"), which is indirectly owned in equal proportion by the Company and the Company's independent third-party joint venture partner, China Merchants Shekou Industrial Zone Holdings Co., Ltd. (招商局蛇口工业区控股股份有限公司) ("**CMSK**").
3. The Loan will be used by the Hospital Company for capital expenditure, renovations and the procurement of equipment and systems by the Changshu Hospital.
4. The Loan is secured by:
  - (a) corporate guarantees by each of the Company (the "**Company Guarantee**") and CMSK in favour of the Lender for 50% of the Loan respectively, in proportion to their respective effective shareholding in the Hospital Company; and
  - (b) comfort letters by each of the Company (the "**Comfort Letter**") and CMSK in favour of the Lender that the Hospital Company's obligations under the Loan Agreement would be satisfied.
5. Neither the entry into the Loan Agreement by the Hospital Company nor the provision of the Company Guarantee and Comfort Letter by the Company is expected to have any material impact on the earnings per share or the net tangible assets of the Company for the financial year ending 31 December 2022.
6. None of the Directors, Chief Executive Officer and controlling shareholders of the Company or any of their respective associates has any interest, direct or indirect, in the transactions contemplated herein.

---

<sup>1</sup> Based on the exchange rate of SGD 1 : RMB 4.781.

**OUE Lippo Healthcare Limited**

Company Registration No. 201304341E

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 Web: [www.ouelh.com](http://www.ouelh.com)

7. The Company will make further announcements, in compliance with the requirements of the Catalist Rules, as and when there are material developments in respect of the transactions and/or other matters contemplated by this announcement. Shareholders and potential investors of the Company should exercise caution when trading in the shares of the Company. In the event of any doubt as to the action they should take, shareholders should consult their financial, tax, legal or other professional advisers.

By Order of the Board

**OUE Lippo Healthcare Limited**

Mr. Yet Kum Meng  
Chief Executive Officer and Executive Director  
29 July 2022

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

*The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.*